Literature DB >> 29903931

Heterogeneity in Metastatic Breast Cancer 18F-Fluoroestradiol Uptake: Clinically Actionable, Biologically Illuminating?

Brenda F Kurland1,2, Steffi Oesterreich2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29903931      PMCID： PMC6071507          DOI： 10.2967/jnumed.118.214304

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  18 in total

1.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  PLoS Med       Date:  2012-05-29       Impact factor: 11.069

2.  Genetic and phenotypic diversity in breast tumor metastases.

Authors:  Vanessa Almendro; Hee Jung Kim; Yu-Kang Cheng; Mithat Gönen; Shalev Itzkovitz; Pedram Argani; Alexander van Oudenaarden; Saraswati Sukumar; Franziska Michor; Kornelia Polyak
Journal:  Cancer Res       Date:  2014-01-21       Impact factor: 12.701

3.  18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.

Authors:  Yingbing Wang; Karen L Ayres; Debra A Goldman; Maura N Dickler; Aditya Bardia; Ingrid A Mayer; Eric Winer; Jill Fredrickson; Carlos L Arteaga; José Baselga; Henry C Manning; Umar Mahmood; Gary A Ulaner
Journal:  Clin Cancer Res       Date:  2016-12-23       Impact factor: 12.531

4.  Visual versus quantitative assessment of intratumor 18F-FDG PET uptake heterogeneity: prognostic value in non-small cell lung cancer.

Authors:  Florent Tixier; Mathieu Hatt; Clemence Valla; Vincent Fleury; Corinne Lamour; Safaa Ezzouhri; Pierre Ingrand; Remy Perdrisot; Dimitris Visvikis; Catherine Cheze Le Rest
Journal:  J Nucl Med       Date:  2014-06-05       Impact factor: 10.057

5.  Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.

Authors:  Michel van Kruchten; Elisabeth G de Vries; Andor W Glaudemans; Meta C van Lanschot; Martijn van Faassen; Ido P Kema; Myles Brown; Carolien P Schröder; Erik F de Vries; Geke A Hospers
Journal:  Cancer Discov       Date:  2014-11-07       Impact factor: 39.397

6.  Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.

Authors:  Brenda F Kurland; Lanell M Peterson; Jean H Lee; Hannah M Linden; Erin K Schubert; Lisa K Dunnwald; Jeanne M Link; Kenneth A Krohn; David A Mankoff
Journal:  J Nucl Med       Date:  2011-09-08       Impact factor: 10.057

7.  Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader.

Authors:  Pedram Heidari; Francis Deng; Shadi A Esfahani; Alicia K Leece; Timothy M Shoup; Neil Vasdev; Umar Mahmood
Journal:  Clin Cancer Res       Date:  2015-01-21       Impact factor: 12.531

8.  Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification?

Authors:  Dominique Sighoko; Juxin Liu; Ningqi Hou; Paul Gustafson; Dezheng Huo
Journal:  Oncologist       Date:  2014-05-07

9.  Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.

Authors:  Brenda F Kurland; Lanell M Peterson; Jean H Lee; Erin K Schubert; Erin R Currin; Jeanne M Link; Kenneth A Krohn; David A Mankoff; Hannah M Linden
Journal:  Clin Cancer Res       Date:  2016-06-24       Impact factor: 12.531

10.  18F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients.

Authors:  Hilde H Nienhuis; Michel van Kruchten; Sjoerd G Elias; Andor W J M Glaudemans; Erik F J de Vries; Alfons H H Bongaerts; Carolien P Schröder; Elisabeth G E de Vries; Geke A P Hospers
Journal:  J Nucl Med       Date:  2018-03-30       Impact factor: 10.057
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.